Vaccination against the HER-2/neu oncogenic protein

Endocrine-Related Cancer

Volumn 9, Issue 1, 2002, Pages 33-44

  Bernhard, H ^a   Salazar, L ^a   Schiffman, K ^a   Smorlesi, A ^a   Schmidt, B ^a   Knutson, K L ^a   Disis, M L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FLT3 LIGAND; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOPROTEIN; P 369 377; PEPTIDE DERIVATIVE; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CELL STIMULATION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; ONCOGENE NEU; REVIEW; VACCINATION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS; FEMALE; HUMANS; MALE; NEOPLASMS; RECEPTOR, ERBB-2; VACCINES, SUBUNIT;

EID: 0036213468     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0090033     Document Type: Review

References (80)

1. + T-cells
2. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
3. Histological and biological evolution of human premalignant breast disease
4. Phenotypic analysis of antigen-specific T lymphocytes
5. TCR gamma delta bearing T lymphocytes infiltrating human primary cutaneous melanomas
6. The gp130-stimulating designer cytokine hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells
7. Gamma delta T-cells in host defense and epithelial cell biology
8. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
9. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
10. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T-cells for melanoma immunotherapy in human MHC class I-transgenic mice
11. Humanization of an anti-p185HER2 antibody for human cancer therapy
12. Therapy with cultured T-cells: Principles revisited
13. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma
14. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
15. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine
16. HER-2/neu oncogenic protein: Issues in vaccine development
17. In vitro generation of human cytotoxic T-cells specific for peptides derived from the HER-2/neu proto-oncogene protein
18. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines
19. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein
20. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
21. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
22. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
23. Flt2 ligand as a vaccine adjuvant in associatioin with HER-2/neu peptide based vaccines in patients with HER-2/neu overexpressing cancers
24. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
25. Heterogeneous T-cell response to MAGE-A10(254-262): High avidity-specific cytolytic T lymphocytes show superior antitumor activity
26. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
27. Changes in a HER-2/neu peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: Implication for optimization of antigen presentation and tumor-specific CTL induction
28. Gamma delta cells regulate autoimmunity
29. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
30. Cytotoxic T-cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
31. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
32. Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity
33. Expansion of HER-2/neu specific T-cells ex vivo following immunization with a HER-2/neu peptide-based vaccine
34. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
35. Immunization of cancer patients with a HER-2/neu HLA-A2 peptide, p369-377, results in short-lived peptide specific immunity
36. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes
37. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
38. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
39. Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo
40. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo
41. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
42. Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer
43. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
44. In vivo generation of human dendritic cell subsets by Flt3 ligand
45. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
46. + hemopoietic progenitor cells
47. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells
48. Anti-HER2 monoclonal antibody trastuzumab enhances cytolytic activity of class I restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells
49. Induction of anti-self-immunity to cure cancer
50. The ErbB signaling network: Receptor heterodimerization in development and cancer
51. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu
52. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
53. Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant
54. Restoration of viral immunity in immunocompromised humans by the adoptive transfer of T-cell clones
55. + T-helper and a T-killer cell
56. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
57. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
58. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation
59. Generation and expansion of HER2-reactive T-cell clones for adoptive immunotherapy
60. Driver clones and determinant spreading
61. Dominance and crypticity of T-cell antigenic determinants
62. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope
63. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
64. Flt3-ligand (Flt3l), as a vaccine adjuvant, results in the generation of antigen-specific IFNγ producing T-cells after immunization
65. +), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells
66. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T-cell epitope
67. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer
68. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters
69. Epitope spreading
70. Nitric oxide inhibits the proliferation of T-helper 1 and 2 lymphocytes without reduction in cytokine secretion
71. First-line herceptin((r)) monotherapy in metastatic breast cancer
72. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity
73. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer
74. Localization of T-cell receptor (TCR)-gamma delta + T-cells into human colorectal cancer: Flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes
75. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
76. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: Implications for vaccine design
77. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
78. Expansion and immunological study of human tumor infiltrating gamma/delta T lymphocytes in vitro
79. + tumors
80. Accumulation of gamma/delta T-cells in human dysgerminoma and seminoma: Roles in autologous tumor killing and granuloma formation